Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13502MR)

This product GTTS-WQ13502MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13502MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15974MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ4324MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ11603MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ2039MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ13691MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ10776MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ6710MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ216MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW